Atlas Trials

Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma

Clinical trial NCT00203866 · TERMINATED

Trial details

NCT number
NCT00203866
Sponsor
University of Chicago
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Renal Cell Carcinoma
Start date
2003-10-01
Primary completion
2007-03-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.